Alzheimer's disease Mental and Behavioural Disorders Dementia in Alzheimer disease
Conditions
Interventions
Amyloid PET imaging to visualise in vivo presence of amyloid deposits in the brain.
Sponsors
Sussex Partnership NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged >40 referred to memory clinic 2. Presence of memory complaint suspicious of AD 3. Below normal scores on cognitive testing (CAMCOG, ACE III or sMMSE scores below the normal range) 4. Presence of specific co-morbid illnesses known to affect cognition and to complicate the diagnosis of Alzheimer’s disease, namely depression and vitamin B12 deficiency 5. MRI and/or CT brain scanning done previously as part of routine diagnostic process
Exclusion criteria
Exclusion criteria: 1. Evidence obtained from history, physical examination or investigations which clearly support the diagnosis of conditions such as vascular dementia, dementia with Lewy bodies and frontotemporal dementia 2. Lack of ability to give informed consent 3. Inability to undertake PET scanning or previous allergic reaction to injected investigative nuclear medicine tracers 4. Positive pregnancy test in premenopausal women and breastfeeding 5. Inability to undertake PET scanning
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is to answer the question on whether the targeted use of the newly licensed amyloid PET imaging improves the diagnostic accuracy in patients presenting with cognitive impairment in addition to depression and/or vitamin B12 deficiency. This will be measured by calculating the number of patients whose diagnosis has changed post scan based on clinical decision. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinician confidence levels in the diagnosis measured pre and post scan using personally administered Likert scales 2. Distribution of amyloid in amyloid positive patients measured by amyloid PET imaging | — |
Countries
United Kingdom
Outcome results
None listed